CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01848990 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

456

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: Commercial Hylenex® recombinant (hyaluronidase human injection)
DRUG: Precommercial Hylenex recombinant (hyaluronidase human injection)
DRUG: Insulin lispro
DRUG: Insulin aspart
DRUG: Insulin glulisine

Sponsor

Halozyme Therapeutics